Phase 4 N=49 Compare Anti-inflammatory Dentifrices
Gingivitis
Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Phase 3 N=39 Collection of Gingival Crevicular Fluid From Periodontitis Patients
Gingival Diseases
Primary: Metabolite Associated With Inflammation (Cadaverine) — 1.119186; 0.92077 ion count — p=<0.05
N/A N=32 Induced Gingivitis & Intra-oral Imaging
Plaque Induced Gingivitis
Primary: Change From Baseline Gingivitis at Day 14 as Measured by Non-invasive Microimaging and Gingival Index. — 0.6; 0.15 units on a scale
N/A N=69 IFI16 is a Periodontitis Modulating Protein
Severe Periodontitis · Acute Inflammatory Response
Primary: Change in Absent in Melanoma 2 (AIM2) mRNA Expression Levels — 0.37; 0.65 fold change — p=0.3
N/A N=51 Kidney and Periodontal Disease Study
Chronic Kidney Disease · Periodontal Disease
Primary: Number of Participants Completing Study Protocol — 17; 34; 14; 30 Participants
N/A N=5,117 Periodontal Disease Prevention Study
Periodontitis
Primary: Percentage of Participants With Tooth Loss Over 16 Year Period — 16.4; 13.8; 22.1; 16.9 percentage of participants
Phase 4 N=113 Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah Population
Periodontal Disease · Type 2 Diabetes Mellitus
Primary: Glycated Hemoglobin A1c — 8; 8.2 percentage of Glycated Hemoglobin A1c
Phase 3 N=19 Investigation of Dental Plaque and Gingival Index
Dental Plaque
Primary: Gingival Margin Plaque Index — 15.4; 12.81 Units on a scale — p=0.05
Phase 4 N=49 Evaluate Inflammation Caused by Gingivitis in Adults
Gingivitis
Primary: Level of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours — 492.2; 326.3 Micrograms — p=0.05
Early Phase 1 N=35 Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model
Gingivitis
Primary: Proportion of Sites That Bleed on Probing
N/A N=34 Effect of Non-surgical Periodontal Therapy on Gingival Crevicular Fluid Interleukin-21 Levels
Chronic Peridontitis Patients · Chronic Gingivitis · Healthy
Primary: Pocket Depth — 1.60; 2.50; 6.75 millimetres
Phase 3 N=602 Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis
Adult Periodontitis
Primary: Change in Pocket Depth. — -1.4; -1.6; -1.4 mm
Phase 3 N=15 Train New Examiners Via Modified Gingival Margin Plaque
Dental Plaque
Primary: Mean Gingival Plaque Units — 13.38; 14.29 Units on a scale — p=0.05
N/A N=253 Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease
Gingivitis
Primary: Number of Bleeding Sites at Week 12 — 42.02; 67.36 number of bleeding sites — p=<0.0001
N/A N=80 Iranian Traditional Mouth Rinse Punica Granatum Pleniflora (Golnaar) in Treatment of Gingivitis in Diabetic Patients
Gingivitis
Primary: Plaque Index — 2.3; 2.5; 1.9; 2 units on a scale
Phase 2 N=71 Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population
Plaque · Gingivitis
Primary: Safety and Tolerability of KSL-W as Measured by Soft Tissue Erythema, Ulceration and Sloughing (AEs and SAEs) — 2; 1; 4; 2 Participants
N/A N=60 Activated MMP-8 as Diagnostic Test for Periodontitis
Generalized Chronic Periodontitis
Primary: Percentage of True Positive/Negative aMMP-8 Tests of All Periodontitis Patients (Sensitivity/Specificity) — 87; 60 percentage of true cases (sens./spec.)
Phase 4 N=69 Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis
Gingivitis · Plaque, Dental · Periodontal Diseases
Primary: Degree of Plaque as Assessed by the Turesky Modification of the Quigley-Hein Plaque Index — 0.41; 0.43 score on a scale
Phase 4 N=43 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis
Osteoporosis, Postmenopausal · Periodontitis
Primary: Sost Values for 6th Month — 1389.177; 1085.405; 1596.585; 2131.87 ng/ml — p=<0.01
Phase 3 N=44 Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes
Dental Plaque
Primary: Control Established Plaque in Adults — 2.42; 2.45 Units on a scale — p=<0.05
N/A N=30 The Effectiveness of Brushing and Flossing Sequence on Control of Plaque and Gingival Inflammation
Gingival Inflammation · Plaque · Gingival Bleeding
Primary: Change From Baseline in Mean BPI Index Scores at 2 Weeks — 0.396; -1.028 score on a scale — p=0.022
N/A N=200 A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis
Plaque
Primary: Plaque Index Score Per Participant at 6 Months — 2.12; 2.70; 2.23; 2.84 score on a scale — p=<0.0001
N/A N=23 Clinical Evaluation of Laser Therapy Used as an Adjunct to Non-Surgical Treatment of Gum Disease
Periodontitis Chronic Generalized Moderate · Periodontitis Chronic Generalized Severe
Primary: Probing Pocket Depth — 4.167; 4.273 mm
Phase 2 N=114 Impact of Periodontal Therapy on Patients With Diabetes
Diabetes Mellitus, Type II · Periodontitis
Primary: Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline — -0.25; -0.18 mm — p=0.16
N/A N=20 Single Stage Root Coverage for Gingival Recession With or Without Free Gingival Graft
Gingival Recession
Primary: Recession Height — 1.0; 0.9 mm
Phase 3 N=33 The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics
Periodontal Disease
Primary: HbA1c Levels in Blood — 9.47; 10.27 Percentage — p=0.05
N/A N=36 Macrophage Markers in Periodontal and Peri-implant Health and Disease
Peri-Implantitis · Periodontitis
Primary: CD80 — 7340.34; 10854.71; 6448.43; 9874.8 arbitrary density units
Phase 2 N=127 Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis
Gingival Inflammation
Primary: Incidence of Adverse Events — 19; 10; 3 Participants
N/A N=61 Trial of Toothpaste to Reduce Plaque and Inflammation
Plaque · Inflammation
Primary: Change in Oral Plaque — -1.05; -0.03 log(percentage) — p=0.001